title: The relationship between perphenazine plasma levels and clinical response in acute schizophrenia.
abstract: 1. Twelve patients with schizophrenia according to RDC participated in a double-blind study, comparing two dose levels of perphenazine, 16 or 32 mg, during four weeks. 2. The patients were assessed with a subscale to CPRS and global scores, measuring improvement of regular intervals during four weeks. 3. Blood samples for assay of plasma perphenazine were collected once a week. 4. These results are in many respects in accordance with earlier published data with perphenazine, that is a good clinical response is achieved with a plasma concentration of perphenazine between 1-5 nmol/L. 5. No incidence of severe adverse symptoms were observed.
authors.affiliation: Dept. of Psychiatry, Danderyd Hospital, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Omérov
authors.forename: B
authors.initials: B
authors.lastname: Wistedt
authors.forename: L
authors.initials: L
authors.lastname: Bolvig-Hansen
authors.forename: N E
authors.initials: NE
authors.lastname: Larsen
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010546:Perphenazine / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*
chemical_list: D010546:Perphenazine